ReviewCurrent atherosclerosis reports2003
Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications.
Review in Current atherosclerosis reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Direct Lp(a)-C measurements provide evidence for Apo(a) isoform-dependent cholesterol composition of Lp(a).Journal of lipid research · 2026Article
- Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025Review
- Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease.Current cardiovascular risk reports · 2025Review
- Lipoprotein(a) and lipid profiles of patients awaiting coronary artery bypass graft; a cross sectional study.BMC cardiovascular disorders · 2016Article
- Association of Elevated Serum Lipoprotein(a), Inflammation, Oxidative Stress and Chronic Kidney Disease with Hypertension in Non-diabetes Hypertensive Patients.Indian journal of clinical biochemistry : IJCB · 2016Article
- Oxidized lipoprotein(a) and cardio-ankle vascular index (CAVI) in hypertensive subjects.Heart and vessels · 2013Article
- The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.Current atherosclerosis reports · 2011Review
- Enigmatic role of lipoprotein(a) in cardiovascular disease.Clinical and translational science · 2010Article
- Lipoprotein(a) accelerates atherosclerosis in uremic mice.Journal of lipid research · 2010Article
- The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2009Article
- Risk factors for cardiovascular disease and hormone therapy in women.Heart (British Cardiac Society) · 2006Review
- T wave abnormalities, high body mass index, current smoking and high lipoprotein (a) levels predict the development of major abnormal Q/QS patterns 20 years later. A population-based study.BMC cardiovascular disorders · 2006Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Although many epidemiologic studies have pointed at an association between plasma levels of lipoprotein(a) (Lp(a)) and cardiovascular risk, the data obtained have been conflicting because of a number of factors, particularly those dealing with plasma storage, lack of assay standardization, population sample size, age, gender, ethnic variations, and variable disease endpoints. Moreover, the attention has been primarily focused on whole Lp(a), with relatively less emphasis on its constituent apolipoprotein(a) and on the apolipoprotein B100-containing lipoprotein, mainly low-density lipoprotein (LDL), to which apolipoprotein(a) is linked. According to recent studies, small-size apolipoprotein(a) isoforms may represent a cardiovascular risk factor either by themselves or synergistically with plasma Lp(a) concentration. Moreover, the density properties of the LDL moiety may have an impact on Lp(a) pathogenicity. It has also become apparent that Lp(a) can be modified by oxidative events and by the action of lipolytic and proteolytic enzymes with the generation of products that exhibit atherothrombogenic potential. The role of the O-glycans linked to the inter-kringle linkers of apolipoprotein(a) is also emerging. This information is raising the awareness of the pleiotropic functions of Lp(a) and is opening new vistas on pathogenetic mechanisms whose knowledge is essential for developing rational therapies against this complex cardiovascular pathogen.
Indexed as
Identifiers
12573195What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.